Citius Pharmaceuticals Inc

NASDAQ:CTXR   11:28:58 AM EDT
1.40
+0.02 (+1.45%)
Products, Regulatory

Citius Pharmaceuticals Completes Enrollment In The Pivotal Phase 3 Study Of Its Cancer Immunotherapy I/Ontak For The Treatment Of Cutaneous T-Cell Lymphoma

Published: 12/06/2021 14:25 GMT
Citius Pharmaceuticals Inc (CTXR) - Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of Its Cancer Immunotherapy I/ontak for the Treatment of Cutaneous T-cell Lymphoma.
Citius Pharmaceuticals Inc - Topline Study Results Expected in First Half of 2022.
Citius Pharmaceuticals Inc - Biologics License Application (bla) Filing Anticipated in Second Half of 2022.